Edgestream Partners L.P. Has $7.39 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Edgestream Partners L.P. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 37.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,344 shares of the company’s stock after selling 5,043 shares during the period. Edgestream Partners L.P.’s holdings in Eli Lilly and Company were worth $7,392,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. LRI Investments LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $81,000. Westwood Holdings Group Inc. boosted its holdings in Eli Lilly and Company by 5.4% during the 1st quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock worth $2,987,000 after acquiring an additional 196 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Eli Lilly and Company by 71.3% during the 2nd quarter. GAMMA Investing LLC now owns 11,658 shares of the company’s stock worth $10,555,000 after acquiring an additional 4,853 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its stake in shares of Eli Lilly and Company by 9.8% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 3,534 shares of the company’s stock worth $3,200,000 after acquiring an additional 315 shares in the last quarter. Finally, Hudson Valley Investment Advisors Inc. ADV raised its holdings in shares of Eli Lilly and Company by 2.2% in the second quarter. Hudson Valley Investment Advisors Inc. ADV now owns 52,520 shares of the company’s stock valued at $47,551,000 after purchasing an additional 1,129 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Citigroup upped their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Bank of America reduced their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $795.35 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The stock has a market cap of $755.04 billion, a PE ratio of 85.98, a price-to-earnings-growth ratio of 2.99 and a beta of 0.43. The stock has a fifty day moving average of $851.90 and a 200-day moving average of $869.52.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.